Anti-leucine-rich glioma-inactivated 1 encephalitis: two case reports and a review of the literature

被引:1
|
作者
Karvigh, Sanaz Ahmadi [1 ]
Salehizadeh, Saeideh [1 ]
Vahabizad, Fahimeh [1 ]
机构
[1] Univ Tehran Med Sci, Sina Hosp, Dept Neurol, Tehran, Iran
关键词
LGI1; Faciobrachial dystonic seizure (FBDS); Basal ganglia; Immunotherapy; Rituximab; Autoimmune encephalitis; FACIOBRACHIAL DYSTONIC SEIZURES; LGI1; IMMUNOTHERAPY; ANTIBODIES; RITUXIMAB; THERAPY; CASPR2;
D O I
10.1186/s13256-022-03650-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Anti-leucine-rich glioma-inactivated 1 encephalitis is a newly emerged entity characterized by frequent faciobrachial dystonic seizures and a wide spectrum of subacute clinical symptoms such as other seizure types, mood and behavioral changes, and memory loss. We should be aware of differentiating this diagnosis from psychogenic nonepileptic seizures. Mesial temporal, limbic structures, and basal ganglia are the most commonly involved regions. Case presentation Here we review the available data, and report on two young Iranian (White) females, 24 and 18 years old, who represent distinct aspects of the disease. The clinical presentation and degree of tissue involvement varies to some extent in the two reported cases. Case 1 had prominent neuropsychiatric symptoms and suffered from frequent faciobrachial dystonic seizures with more significant basal ganglia involvement, whereas case 2 suffered from severe memory decline and dialeptic seizures along with mesial temporal involvement. Symptoms were refractory to usual treatment and prompt immunotherapy was needed. Conclusions This disease has a rather favorable outcome provided that treatment is initiated early. However, resistance to first-line treatment, relapses, and long-term complications highlight the need to establish reliable biomarkers to distinguish different subtypes of this disorder to predict the clinical outcome and prognosis, and to refine management.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Clinical features of patients with anti-leucine-rich glioma inactivated-1 protein associated encephalitis: a Chinese case series
    Yang, Xue
    Li, An-Ning
    Zhao, Xiu-He
    Liu, Xue-Wu
    Wang, Sheng-Jun
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2019, 129 (08) : 754 - 761
  • [32] Mycophenolate mofetil reduces the risk of relapse in anti-leucine-rich glioma-inactivated protein 1 encephalitis: a prospective observational cohort study
    Liu, Mange
    Xu, Xiaolu
    Fan, Siyuan
    Ren, Haitao
    Zhao, Yanhuan
    Guan, Hongzhi
    NEUROLOGICAL SCIENCES, 2024, 45 (01) : 253 - 260
  • [33] Clinical Features, Immunotherapy, and Outcomes of Anti-Leucine-Rich Glioma-Inactivated-1 Encephalitis
    Huang, Xiaoqin
    Fan, Chunqiu
    Gao, Lehong
    Li, Liping
    Ye, Jing
    Shen, Huixin
    JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2022, 34 (02) : 141 - 148
  • [34] Neurological, psychiatric, and sleep investigations after treatment of anti-leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis in Spain: a prospective cohort study
    Munoz-Lopetegi, Amaia
    Guasp, Mar
    Prades, Laia
    Martinez-Hernandez, Eugenia
    Rosa-Justicia, Mireia
    Patricio, Victor
    Armangue, Thais
    Rami, Lorena
    Borras, Roger
    Castro-Fornieles, Josefina
    Compte, Albert
    Gaig, Carles
    Santamaria, Joan
    Dalmau, Josep
    LANCET NEUROLOGY, 2024, 23 (03) : 256 - 266
  • [35] Autoimmune cerebellar ataxia associated with anti-leucine-rich glioma-inactivated protein 1 antibodies: Two pediatric cases
    Zhang, Weihua
    Ren, Haitao
    Jie, Deng
    Ren, Changhong
    Ji, Zhou
    Anna, Zhou
    Guan, Hongzhi
    Ren, Xiaotun
    JOURNAL OF NEUROIMMUNOLOGY, 2022, 370
  • [36] Anti-leucine-rich Glioma-inactivated-1 Encephalitis with Faciobrachial Dystonic Seizures and Behavioral Problems: A Case Report
    Adhikari, Ayush
    Subedi, Ram Chandra
    Acharya, Subi
    Paudel, Raju
    JOURNAL OF NEPAL MEDICAL ASSOCIATION, 2020, 58 (227) : 487 - 490
  • [37] Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies
    Finke, Carsten
    Pruess, Harald
    Heine, Josephine
    Reuter, Sigrid
    Kopp, Ute A.
    Wegner, Florian
    Bergh, Florian Then
    Koch, Sebastian
    Jansen, Olav
    Muente, Thomas
    Deuschl, Guenther
    Ruprecht, Klemens
    Stoecker, Winfried
    Wandinger, Klaus-Peter
    Paul, Friedemann
    Bartsch, Thorsten
    JAMA NEUROLOGY, 2017, 74 (01) : 50 - 59
  • [38] Seizure semiology in leucine-rich glioma-inactivated protein 1 antibody-associated limbic encephalitis
    Chen, Chao
    Wang, Xiu
    Zhang, Chao
    Cui, Tao
    Shi, Wei-Xiong
    Guan, Hong-Zhi
    Ren, Hai-Tao
    Shao, Xiao-Qiu
    EPILEPSY & BEHAVIOR, 2017, 77 : 90 - 95
  • [39] Cortical metabolic characteristics of anti-leucine-rich glioma-inactivated 1 antibody encephalitis based on 18F-FDG PET
    Wang, Kai
    Zhao, Xiaobin
    Yuan, Leilei
    Chen, Qian
    Wang, Qun
    Ai, Lin
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [40] 18F-FDG PET/CT in Anti-Leucine-Rich Glioma-Inactivated 1 Antibody Encephalitis Typical Pattern and Follow-up
    Caquot, Pierre-Ambroise
    Zizi, Ghali
    Lelievre, Maxime
    Dejust, Sebastien
    Morland, David
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (03) : 250 - 251